At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- VERVE-102 (drug)
- How long the study runs
- Study runs about 42 months (dates as stated)
- About the drug or intervention
- VERVE-102 — drug: Intravenous (IV) infusion
- Patient visit burden
- Not specified by the sponsor
In plain English
This study is testing a treatment called VERVE-102 in people with familial hypercholesterolemia (an inherited condition causing very high cholesterol) or premature coronary artery disease (heart disease that starts earlier than usual). It is sponsored by Verve Therapeutics, Inc.
Who can take part
- You have a diagnosis of heterozygous familial hypercholesterolemia (an inherited form of high cholesterol from one parent), or premature coronary artery disease (heart disease that develops early in life)
Who may not be able to
- You have homozygous familial hypercholesterolemia (an inherited form of high cholesterol from both parents)
- You have liver disease now, or have had long-term liver disease in the past
- You are currently taking a PCSK9 inhibitor (a cholesterol-lowering medicine), or took one within a time period set out in the study rules
- You have blood test results that are significantly abnormal, as defined by the study rules
What taking part involves
- • Not stated — ask the trial team
Time commitment: Not stated — ask the trial team
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Testing a treatment
- Ages
- 18 Years to 70 Years
- Who
- All
- Number of participants
- 85
- Started
- 2024-04-30
- Last checked
- 2026-08
Plain English Summary
What is this study?
- • Testing a new treatment for heterozygous familial hypercholesterolemia
- • Phase1 - 85 participants
- • VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C
Who can take part?
- • Ages 18 Years to 70 Years
- • Diagnosed with heterozygous familial hypercholesterolemia
Where?
- • Birmingham - Clinical Study Center
- • Cambridge - Clinical Study Center
- • Edinburgh - Clinical Study Center
- • London - Clinical Study Center
- • +2 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 70 Years
- Who can join: All genders
What the study is looking for
- ✓Diagnosis of HeFH or premature CAD
Who cannot take part
- ✗Homozygous familial hypercholesterolemia
- ✗Active or history of chronic liver disease
- ✗Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe
- ✗Clinically significant or abnormal laboratory values as defined by the protocol
See the full criteria
Where Is This Study? (6 UK sites)
Clinical Study Center
Birmingham, United Kingdom
Clinical Study Center
Cambridge, United Kingdom
Clinical Study Center
Edinburgh, United Kingdom
Clinical Study Center
London, United Kingdom
Clinical Study Center
Manchester, United Kingdom
Clinical Study Center
Nottingham, United Kingdom
How to Get in Touch
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Sponsor contactCONTACT
Physicians interested in becoming principal investigators please contact
Sponsor contactCONTACT